2024 - Allogene

Read more about the article Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Post author:andrewkaretas
Post published:December 9, 2024
Post category:CD19 Scientific Publications

Piper Sandler 36th Annual Healthcare Conference

Post author:Allogene Therapeutics
Post published:December 3, 2024
Post category:Uncategorized

The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.

December 3, 2024 8:00 AM EST : Piper Sandler 36th Annual Healthcare Conference

Post author:Allogene Therapeutics Events
Post published:December 3, 2024
Post category:Uncategorized

The Citizens JMP Hematology and Oncology Summit

Post author:Allogene Therapeutics
Post published:December 2, 2024
Post category:Uncategorized

The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.

December 2, 2024 11:00 AM EST : The Citizens JMP Hematology and Oncology Summit

Post author:Allogene Therapeutics Events
Post published:December 2, 2024
Post category:Uncategorized

November 20, 2024 6:30 AM EST : Jefferies London Healthcare Conference

Post author:Allogene Therapeutics Events
Post published:November 20, 2024
Post category:Uncategorized

Jefferies London Healthcare Conference

Post author:Allogene Therapeutics
Post published:November 20, 2024
Post category:Uncategorized

The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.

Stifel 2024 Healthcare Conference

Post author:Allogene Therapeutics
Post published:November 18, 2024
Post category:Uncategorized

The Investor Relations website contains information about Allogene Therapeutics's business for stockholders, potential investors, and financial analysts.